Triton completes acquisition of a majority stake in Atnahs

Frankfurt (Germany), Basildon (United Kingdom), August 8, 2019 – Funds advised by Triton have successfully completed the acquisition of a majority stake of Atnahs, a specialty pharmaceutical business, focussed on the acquisition, development and marketing of mature branded medicines. Terms and conditions of the transaction are not disclosed.